drugset / Trial / NCT04557475

Transplacental Aspirin Therapy for Early Onset Fetal Growth Restriction

NCT04557475 ↗

Phase 3 Withdrawn Johns Hopkins University
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this investigation is to evaluate the ability of maternal aspirin (ASA) therapy to prevent preterm birth for fetal indications prior to 32 weeks gestation in women with early onset Fetal Growth Restriction (FGR). Aspirin is a commonly used medication that blocks blood platelets from clumping. Aspirin crosses the placenta in a dose dependent mode. There is preliminary evidence in smaller studies that aspirin can block fetal platelet clumping and, therefore, slow down the progression of placental disease under specific circumstances. The optimal time for aspirin to work is when the fetus' placental dysfunction is still mild. The goal of this research study is to show if fetuses that receive aspirin through maternal intake at a dose shown to affect fetal platelet aggregation will be less likely to deliver before 32 weeks for fetal deterioration. The outcomes of patients that receive aspirin will be compared to women that receive standard FGR management but do not take any aspirin. The decision if a study participant receives aspirin or not will be randomly picked. Such a research study is called a randomized controlled trial.

Timeline

Start
2022-06-11
Primary completion
2023-06-11
Completion
2023-06-11

Outcome

Outcome not reported

Stopped: “We are modifying this trial's protocol and will resubmit a new application at a later date.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule — —